OliX Pharmaceuticals Inc. announced the submission of an Investigational New Drug application to the US Food and Drug Administration to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration. The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.AMD is the most common cause of blindness in the industrialized world, which affects more than 170 million people worldwide. AMD presents in 2 forms, geographic atrophy and neovascular AMD.

Although treatments exist for many patients with neovascular AMD, a substantial number of patients remain insufficiently treated, and there is no FDA- approved drug for GA up to date. Therefore, the development of novel and safe AMD treatments presents as an important unmet medical need that OliX addresses with the development of OLX10212 for both indications. According to GlobalData, the global market for the treatment of AMD is expected to grow from USD 11.7 billion in 2022 to USD 18.7 billion in 2028.